[6]-Gingerol exhibits potent anti-mycobacterial and immunomodulatory activity against tuberculosis.

Autor: Bhaskar A; Signal Transduction Laboratory-1, National Institute of Immunology, New Delhi, India. Electronic address: abhaskar@nii.ac.in., Kumari A; International Centre for Genetic Engineering and Biotechnology, New Delhi, India., Singh M; Special Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi, India., Kumar S; International Centre for Genetic Engineering and Biotechnology, New Delhi, India., Kumar S; Signal Transduction Laboratory-1, National Institute of Immunology, New Delhi, India., Dabla A; Signal Transduction Laboratory-1, National Institute of Immunology, New Delhi, India., Chaturvedi S; International Centre for Genetic Engineering and Biotechnology, New Delhi, India., Yadav V; Department of Microbiology, Central University of Haryana, Haryana, India., Chattopadhyay D; National Institute of Traditional Medicine, Belagavi, Karnataka, India., Prakash Dwivedi V; International Centre for Genetic Engineering and Biotechnology, New Delhi, India. Electronic address: ved@icgeb.res.in.
Jazyk: angličtina
Zdroj: International immunopharmacology [Int Immunopharmacol] 2020 Oct; Vol. 87, pp. 106809. Date of Electronic Publication: 2020 Jul 18.
DOI: 10.1016/j.intimp.2020.106809
Abstrakt: The currently available anti-tuberculosis treatment (ATT) comprises exclusively of anti-bacterial drugs, is very lengthy, has adverse side effects on the host and leads to the generation of drug-resistant variants. Therefore, a combination therapy directed against the pathogen and the host is required to counter tuberculosis (TB). Here we demonstrate that [6]-Gingerol, one of the most potent and pharmacologically active ingredients of ginger restricted mycobacterial growth inside the lungs, spleen and liver of mice infected with Mycobacterium tuberculosis (Mtb). The spleen of [6]-Gingerol treated mice displayed increased expression of pro-inflammatory cytokines and enhanced Th1/Th17 responses confirming the immunomodulatory action of [6]-Gingerol. Finally, [6]-Gingerol displayed an excellent potential as an adjunct drug, along with front line anti-TB drug isoniazid. Interestingly, [6]-Gingerol displayed stark anti-tubercular activity against dormant/starved bacilli and drug-resistant variants of Mtb. Taken together, these results indicate strong prospects of [6]-Gingerol as an adjunct anti-mycobacterial and immunomodulatory drug for the treatment of drug-susceptible and drug-resistant strains of TB.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2020 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: